Table 3.
Steady-state metabolic parameters in placebo and rimonabant groups
| Week 0 | Week 2 | Week 6 | Week 12 | Week 16 | |
|---|---|---|---|---|---|
| Placebo | |||||
| Insulin, pM | 307 ± 59 | 262 ± 17 | 286 ± 23 | 299 ± 19 | 324 ± 19 |
| MCR, ml·kg−1·min−1 | 17.1 ± 1.7 | 17.7 ± 1.0 | 16.5 ± 1.3 | 15.5 ± 0.9 | 14.3 ± 0.8 |
| Ginf, mg·kg−1·min−1 | 7.9 ± 1.1 | 7.6 ± 1.4 | 8.1 ± 1.1 | 10.2 ± 1.4 | 9.2 ± 0.9 |
| Rd, mg·kg·−1min−1 | 8.3 ± 1.5 | 7.2 ± 1.2 | 7.5 ± 1.0 | 8.9 ± 1.2 | 8.4 ± 0.9 |
| EGP, mg·kg−1·min−1 | −0.3 ± 0.3 | −0.3 ± 0.4 | −0.7 ± 0.6 | −0.8 ± 0.6 | −0.8 ± 0.5 |
| Rimonabant | |||||
| Insulin, pM | 271 ± 36 | 238 ± 13 | 255 ± 12 | 286 ± 25 | 279 ± 13 |
| MCR, ml·kg−1·min−1 | 18.5 ± 1.5 | 19.4 ± 0.9 | 18.0 ± 0.9 | 16.2 ± 0.8 | 16.6 ± 1.0 |
| Ginf, mg·kg−1·min−1 | 5.8 ± 0.8 | 7.9 ± 0.7* | 8.1 ± 0.7* | 9.2 ± 0.9* | 8.8 ± 0.9* |
| Rd, mg·kg−1·min−1 | 7.1 ± 0.7 | 7.3 ± 0.6 | 7.7 ± 0.6 | 8.2 ± 0.9 | 8.6 ± 0.9 |
| EGP, mg·kg−1·min−1 | 1.0 ± 0.6 | −0.4 ± 0.4 | −0.5 ± 0.6 | −0.8 ± 0.7 | −0.5 ± 0.4* |
Values are means ± SE. EGP, endogenous glucose production; Ginf, glucose infusion rate; Rd, glucose disappearance.
*
P < 0.05 vs. week 0.